[{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3||CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Onconova Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Merger","leadProduct":"Tivoxavir Marboxil","moa":"Endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ Onconova Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Onconova Therapeutics"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Tivoxavir Marboxil","moa":"Endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tivoxavir Marboxil","moa":"Endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tivoxavir Marboxil","moa":"Endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tivoxavir Marboxil","moa":"Endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"ON 013105","moa":"G1\/S-specific cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Leukemia and Lymphoma Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Rigosertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase III","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Leukemia and Lymphoma Society","highestDevelopmentStatusID":"10","companyTruncated":"Traws Pharma \/ Leukemia and Lymphoma Society"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Rigosertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Academic GI Cancer Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Rigosertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase III","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Academic GI Cancer Consortium","highestDevelopmentStatusID":"10","companyTruncated":"Traws Pharma \/ Academic GI Cancer Consortium"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Rigosertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase III","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Traws Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Traws Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Traws Pharma"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Traws Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ Traws Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Traws Pharma \/ Traws Pharma"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Undisclosed","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ON 013105","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Trawsfynydd Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"83-0060","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Traws Pharma \/ Trawsfynydd Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Trawsfynydd Therapeutics"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Travatrelvir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Travatrelvir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TRX-100","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ratutrelvir","moa":"SARS-CoV-2 3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Traws Pharma \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Traws Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
